Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

MYSTERIOUS: Dexcom - You Need To See This

A Second Company Joins the FDA Pilot That Lets Digital Devices Reach Medicare Patients Before Authorization

A blood pressure medication software system joined the FDA TEMPO pilot, a bigger clinical step than the first participant. Here is what changed.

Medical Daily

Is Wall Street Bullish or Bearish on DexCom Stock?

Despite DexCom’s weak performance relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.

Barchart

FDA Names Its First Company in a Pilot That Lets Some Digital Health Devices Skip Premarket Review

The FDA selected Dexcom as the first participant in its TEMPO pilot, which pairs relaxed premarket review with real-world evidence collection.

Medical Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

The FDA Just Cleared the First Over-the-Counter Glucose Monitor for Children

FDA cleared the first OTC glucose monitor for children ages 2+ on June 12. Here's what this means for families managing prediabetes or Type 2 diabetes.

Medical Daily

Earnings Preview: What To Expect From DexCom's Report

DexCom is expected to announce its second-quarter earnings soon, and Wall Street expects the company’s EPS to increase by a double-digit percentage.

Barchart

June Brought Two Major FDA Advances for Children with Type 1 Diabetes: Here's What Each One Does

June 2026 brought two FDA milestones for pediatric diabetes: an OTC kids' CGM and teplizumab for Stage 3 Type 1 diabetes in ages 8–17. Here's what each one does and who qualifies.

Medical Daily

3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend

With GLP-1 usage continuing to rise, a group of unlikely beneficiaries is emerging; stocks in the broader health care sector and even in retail could stand out.

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

3 Stocks Doing the Heavy Lifting in Healthcare’s Rebound

Led by Eli Lilly’s GLP-1 success, Humana’s expanding margins, and DexCom’s medtech growth, the healthcare sector is staging a major market rebound.

MarketBeat

Is DexCom Stock Underperforming the Dow?

DexCom has lagged behind the Dow Jones over the past year, yet analysts remain highly bullish about the stock’s outlook.

Barchart

The DexCom Stock Turnaround Is Showing Real Signs of Life

DexCom (DXCM) shares have put together an encouraging short-term bounce as the company maps out a multi-year growth algorithm. The stock currently carries a 8% “Sell” rating, but that’s up from the prior day’s 96% “Sell” rating and 100% “Sell” last week. A positive trend on that indicator. DXCM is...

Barchart

DexCom Maps G8 Launch, Coverage Expansion and Double-Digit Growth at Investor Day

DexCom (NASDAQ:DXCM) used its 2026 Investor Day to outline a long-range plan centered on new product launches, broader insurance coverage for continuous glucose monitoring, international expansion and margin improvement. President and Chief Executive Officer Jake Leach said the company’s next phase

MarketBeat

Are Wall Street Analysts Bullish on DexCom’s Stock?

Although DexCom has significantly underperformed the broader market over the past year, Wall Street analysts continue to maintain a very bullish outlook on the company’s long-term growth prospects.

Barchart

Sell in May and Go Away—Starting With These 3 Stocks

Oxford Club's Marc Lichtenfeld identifies three stocks worth selling in May—DexCom, Colgate-Palmolive, and Oracle—and breaks down the risks behind each call.

MarketBeat

3 Reasons Analysts Love DexCom

Continuous glucose monitoring devices are vital to those with type 2 diabetes, and DexCom is cementing its position as a leader in this growing market.

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

DexCom’s Quarterly Earnings Preview: What You Need to Know

DexCom is set to report its first-quarter results at month-end, and the Street is expecting a solid double-digit expansion in earnings.

Barchart

Is DexCom Stock Underperforming the Nasdaq?

DexCom has underperformed the Nasdaq Composite over the past year, yet analysts remain highly optimistic about the stock’s future.

Barchart

What Are Wall Street Analysts' Target Price for DexCom Stock?

Despite DexCom’s weak performance relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.

Tom’s Guide

5 things I hope to see on the Garmin Fenix 9, including the return of a smaller size

The Garmin Fenix 9 could launch later this year and while it’s unlikely to be a major upgrade on the Fenix 8 Pro, I’m hoping to see these five features on a new watch.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Is DexCom Stock Underperforming the S&P 500?

DexCom has considerably underperformed the S&P 500 over the past year, but analysts are highly optimistic about the stock’s prospects.

Barchart

DexCom Stock: Is Wall Street Bullish or Bearish?

Although DexCom stock has trailed the broader market over the past year, analysts remain bullish about its prospects.

Benzinga

Why TAL Education, Shake Shack And DexCom Just Appeared On Value Investors' Radars

A trio of stocks made an impressive leap in their Benzinga Edge value scores this week, with one standout making a 138% jump. The three companies that have caught the eye of value investors are TAL Education Inc (NYSE:TAL), Shake Shack Inc (NYSE:SHAK) and DexCom Inc (NASDAQ:DXCM).

MarketBeat

From Dividends to Growth: Why These 3 Stocks Stand Out in 2025

Dividend stocks tend to be stable performers; these companies have a history of recent rallies or the potential to grow in the future.

Benzinga

DexCom Faces New Reports Of Deaths Linked To G7 Glucose Monitor

DexCom Inc (NASDAQ:DXCM) is facing renewed scrutiny after three people with diabetes reportedly died following issues with its G7 continuous glucose monitor, according to adverse event filings submitted to the Food and Drug Administration in September.

Barchart

DexCom Earnings Preview: What to Expect

DexCom is scheduled to announce its fiscal third-quarter earnings later this month, and analysts project a double-digit profit rise.

Benzinga

Short Report Alleges Dexcom Sold Faulty G7 Device Cited By FDA

Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device.

1 2 3 4

People

Marc Lichtenfeld

10 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.